Med24
metabolic-therapy 28. 10. 2026 • 2 min read • Pediatric blood & cancer (PubMed)

Population-Based Assessment of Cardiometabolic Late Effects in 5-Year Survivors of Pediatric Acute Lymphoblastic Leukemia.

INTRODUCTION: Survival rates for pediatric acute lymphoblastic leukemia (ALL) have improved substantially, shifting attention toward long-term health. Epidemiologic data on survivors of pediatric ALL from large, population-based cohorts, particularly in early survivorship, is limited. We addressed this gap by...

Israelin lääkärimissio – uudet politiikat ja ratkaisut terveydenhuollon haasteisiin.

A retrospective cohort study examined cardiometabolic late effects in pediatric acute lymphoblastic leukemia (ALL) survivors. The research utilized linked data from the Arkansas Central Cancer Registry and Arkansas All-Payer Claims Database to compare survivors with cancer-free peers five years after diagnosis. ALL survivors were matched with controls based on several factors.

Key Clinical Findings

The study identified 142 ALL survivors (aged 4-30 years) and matched them with 426 cancer-free peers based on sex, race, ethnicity, birth year, Medicaid enrollment history, and county of residence. Cardiometabolic outcomes were assessed using claims-based diagnoses. Results indicated a significantly higher prevalence of cardiometabolic conditions among ALL survivors compared to matched controls. Specifically, ALL survivors experienced a 10.6% prevalence of cardiometabolic conditions, compared to 1.2% in the matched controls (p < 0.01). The survivors demonstrated a higher prevalence of hypertension (4.9% vs. 0.9%; p < 0.01) and diabetes mellitus (4.9% vs. 0.2%; p < 0.01). These differences were more pronounced among survivors aged 14 years and older, with 20.4% experiencing at least one cardiometabolic condition compared to 2.0% in the control group (p < 0.01).

Sponsored content

Implications and Future Directions

The study highlights an elevated cardiometabolic risk in pediatric ALL survivors as early as five years after diagnosis, particularly during adolescence. Early screening and preventive strategies are needed to reduce the long-term cardiometabolic burden associated with this population. Cardiometabolic conditions represent a significant concern for this patient group.”

Original Scientific Source
Pediatric blood & cancer (PubMed)
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Nanotechnology-Driven 18F-FDG Imaging to Understand the Change in Insulin Sensitivity: Current Evidence, Methodological Gaps, and Translational Challenges.
metabolic-therapy

Nanotechnology-Driven 18F-FDG Imaging to Understand the Change in Insulin Sensitivity: Current Evidence, Methodological Gaps, and Translational Challenges.

Insulin resistance is an important metabolic derangement contributing to the pathogenesis of type 2 diabetes, obesity, metabolic syndrome, and other chronic diseases, underlining the requirement for techniques that enable in vivo analysis of tissue-specific glucose metabolism. 18F-fluorodeoxyglucose positron emission...

10. 11. 2026 Read article →
Cardiometabolic Abnormalities among Normal-Weight Adults: Prevalence and Associated Sociodemographic and Lifestyle Factors in a Large Spanish Cohort.
metabolic-therapy

Cardiometabolic Abnormalities among Normal-Weight Adults: Prevalence and Associated Sociodemographic and Lifestyle Factors in a Large Spanish Cohort.

BACKGROUND: Although body mass index (BMI) is widely used to assess obesity-related health risks, it may fail to detect individuals with normal weight who present with significant cardiometabolic abnormalities. This phenotype, often overlooked in clinical practice, is associated with increased risk of cardiovascular...

30. 10. 2026 Read article →
Advertisement